FDA approves VYALEV for adults living with advanced parkinson's disease
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
The first phase of the Aptivate Achi Bhookh Fest reached over 8,200 households
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
Akums Drugs will undertake this development and commercialization in India
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
Subscribe To Our Newsletter & Stay Updated